L
Luc Bracoud
Researcher at BioClinica
Publications - 36
Citations - 900
Luc Bracoud is an academic researcher from BioClinica. The author has contributed to research in topics: Population & Internal medicine. The author has an hindex of 12, co-authored 32 publications receiving 699 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial
Serge Gauthier,Howard Feldman,Lon S. Schneider,Gordon K. Wilcock,Giovanni B. Frisoni,Jiri Hardlund,Hans J Moebius,Peter Bentham,Karin A Kook,Damon Wischik,Bjoern Schelter,Charles S Davis,Roger T. Staff,Luc Bracoud,Kohkan Shamsi,John Storey,Charles R. Harrington,Claude M. Wischik +17 more
TL;DR: The primary analysis for this study was negative, and the results do not suggest benefit of LMTM as an add-on treatment for mild to moderate Alzheimer's disease, but the prespecified primary analyses did not show any treatment benefit at either of the doses tested for the coprimary outcomes.
Journal ArticleDOI
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Vladimir Coric,Stephen Salloway,Christopher H. van Dyck,Bruno Dubois,Niels Andreasen,Mark Brody,Craig Curtis,Hilkka Soininen,Stephen G. Thein,Thomas Shiovitz,Gary Pilcher,Steven H. Ferris,Susan Colby,Wendy Kerselaers,Randy C. Dockens,Holly Soares,Stephen Kaplita,Feng Luo,Chahin Pachai,Luc Bracoud,Mark A. Mintun,Joshua D. Grill,Ken Marek,John Seibyl,Jesse M. Cedarbaum,Charles F. Albright,Howard Feldman,Robert M. Berman +27 more
TL;DR: Avagacestat did not demonstrate efficacy and was associated with adverse dose-limiting effects in this PDAD population, which had higher rates of clinical progression to dementia and greater brain atrophy compared with CSF biomarker-negative participants.
Journal ArticleDOI
Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.
Gordon K. Wilcock,Serge Gauthier,Giovanni B. Frisoni,Jianping Jia,Jiri Hardlund,Hans J Moebius,Peter Bentham,Karin A Kook,Bjoern Schelter,Damon Wischik,Charles S Davis,Roger T. Staff,Vesna Vuksanović,Trevor Ahearn,Luc Bracoud,Kohkan Shamsi,Ken Marek,John Seibyl,Gernot Riedel,John Storey,Charles R. Harrington,Claude M. Wischik +21 more
TL;DR: The results are consistent with earlier studies in supporting the hypothesis that LMTM might be effective as monotherapy and that 4 mg twice a day may serve as well as higher doses.
Journal ArticleDOI
Tissue Microstructural Changes Are Independently Associated With Cognitive Impairment in Cerebral Amyloid Angiopathy
Anand Viswanathan,Pratik V. Patel,Rosanna Rahman,R. N. Kaveer Nandigam,Catherine Kinnecom,Luc Bracoud,Jonathan Rosand,Hugues Chabriat,Steven M. Greenberg,Eric E. Smith +9 more
TL;DR: The results suggest that global MRI diffusion changes are sensitive to clinically relevant microstructural alterations and may be useful markers of CAA-related tissue damage.
Journal ArticleDOI
Genome-Wide Genotyping Demonstrates a Polygenic Risk Score Associated With White Matter Hyperintensity Volume in CADASIL
Christian Opherk,Mariya Gonik,Marco Duering,R. Malik,Eric Jouvent,D. Hervé,Poneh Adib-Samii,Steve Bevan,Luigi Pianese,Serena Silvestri,Maria Teresa Dotti,Nicola De Stefano,Michael Liem,Elles M. J. Boon,Francesca Pescini,Chahin Pachai,Luc Bracoud,Bertram Müller-Myhsok,Thomas Meitinger,Natalia S. Rost,Leonardo Pantoni,Saskia A J Lesnik Oberstein,Antonio Federico,Michele Ragno,Hugh S. Markus,Elisabeth Tournier-Lasserve,Jonathan Rosand,Hugues Chabriat,Martin Dichgans +28 more
TL;DR: The findings suggest that multiple variants with small effects influence WMH burden in CADASIL, and the identification of these variants and the biological pathways involved will provide insights into the pathophysiology of white matter disease in CADasIL and possibly small vessel disease in general.